Lionco Pharmaceutical Group Co., Ltd. Class A

Lionco Pharmaceutical Group Co., Ltd. Class A

SSSE:603669
4.77
CNY
-0.22
(-4.41%)
-0.18EPS
4.51BMarket Cap

Total Valuation

CNY

As of September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A carries a market capitalization of 4.51B, placing it among publicly traded companies globally. Its enterprise value stands at 4.68B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.51B
Enterprise Value4.68B

Share Statistics

As of September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A has 712.36M shares outstanding.

Shares Outstanding712.36M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 11.18, and the price-to-book ratio stands at 6.91.

PS Ratio11.18
PB Ratio6.91
P/TBV Ratio8.00

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 11.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.68B versus a market cap of 4.51B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales11.67

Financial Position

As of September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 50.07, indicating elevated leverage, while an interest coverage ratio of -5.63 demonstrates limited ability to service its debt obligations.

Current Ratio1.25
Quick Ratio0.33
Debt / Equity50.07
Debt / EBITDA-2.59
Interest Coverage-5.63

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A posted a negative return on equity (ROE) of -18.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -10.77, reflecting losses generated across the asset base. The company generates approximately 1.41M in revenue per employee across its workforce of 284.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.50 indicates how many times Lionco Pharmaceutical Group Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-18.31
Return on Assets (ROA)-10.77
Revenue Per Employee1.41M
Employee Count284.00
Inventory Turnover3.50

Taxes

CNY

Over the twelve months ended September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A recorded 138,522.46 in income tax expense. The company reported a pretax loss of -126.77M and -126.91M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax138,522.46

Stock Price Statistics

CNY

As of the close on November 17, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A's stock has declined approximately 16.02% over the past 52 weeks. The 50-day moving average sits at 5.90, while the 200-day moving average is 5.21.

52-Week Price Change-16.02%
50-Day Moving Average5.90
200-Day Moving Average5.21

Income Statement

CNY

Over the twelve months ended September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A generated 400.80M in revenue and converted that into -126.91M in net income, yielding earnings per share of -0.18. EBITDA reached -126.04M, while operating income came in at -16.08M.

Revenue400.80M
Gross Profit191.15M
Operating Income-16.08M
Pretax Income-126.77M
Net Income-126.91M
EBITDA-126.04M
EBIT-126.04M
Earnings Per Share (EPS)-0.18

Balance Sheet

CNY

As of September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A holds 157.28M in cash and equivalents against 326.63M in total debt, resulting in a net debt position of -118.53M. Total book value stands at 652.33M, with working capital of 117.31M providing operational flexibility.

Cash & Cash Equivalents157.28M
Total Debt326.63M
Net Debt-118.53M
Equity (Book Value)652.33M
Book Value Per Share0.92
Working Capital117.31M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-3.86M

Margins

Over the twelve months ended September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A posted a gross margin of 47.69, reflecting its pricing power and cost economics. The operating margin of -4.01 and net profit margin of -31.66 provide insight into operational efficiency.

Gross Margin47.69
Operating Margin-4.01
Pretax Margin-31.63
Profit Margin-31.66
EBITDA Margin-31.45

Dividends & Yields

Over the twelve months ended September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A paid dividends of 0.00 per share. The dividend payout ratio of -0.37 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -0.40, meaning Lionco Pharmaceutical Group Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Payout Ratio-0.37
Shareholder Yield-0.40

Stock Splits

Lionco Pharmaceutical Group Co., Ltd. Class A's most recent stock split took place on May 26, 2020 with a 5:7 split ratio.

Last Split Date5/26/2020
Split Ratio5:7

Scores

As of September 30, 2026, Lionco Pharmaceutical Group Co., Ltd. Class A has an Altman Z-Score of 5.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score5.30